Background: The incidence of primary central nervous system (CNS) melanocytic neoplasms is relatively low comparing to systemic ones. The performance of the tumor is variable. With poor clinical experience, the diagnosis and treatment of such tumors present to be a challenge. Amelanotic melanoma is an especially rare subtype. Only several cases have been reported. Case presentation: We report a case of intracranial amelanotic melanoma. Preoperative assessment revealed progressive right frontal mass. The patient underwent tumor resection. The pathologic analysis reported amelanotic melanoma of intermediate grade. The further examination of the whole brain and body was negative. The familial history was also negative. The patient recovered uneventfully and went on for radiotherapy and chemotherapy. After a follow-up period of 5 months, the patient was tumor-free. Conclusions: This is the second report about primary CNS amelanotic melanoma. We summarized characteristics of the primary CNS melanocytic lesions and amelanotic melanoma with review of the literature and review of cases of our department.
Background
Primary melanocytic neoplasms of the central nervous system (CNS) belong to the tumors of the meninges. The incidence is less than 0.1%. Some may relate to certain neurocutaneous syndrome. The tumor can affect the entire CNS, with miscellaneous performances. The diagnosis is always difficult before the pathology result is available. And due to the potential of malignant transformation and dissemination, the identification of the original loci is even harder. So the clinical diagnosis and treatment must base on an overall evaluation of a patient. Primary amelanotic melanoma is a special subtype of the melanocytic neoplasm, which is especially rare. We want to share our experiences of primary CNS melanocytic neoplasms and amelanotic melanoma through our cases with review of the literature.
Case presentation

Medical history
A 64-year-old man presented to our department in December 2013 for progressive right frontal mass with dull aching for 9 months. His medical history was unremarkable except for 2 years of hypertension. The familial history was negative, with no neurocutaneous system disorders of the first grade relatives.
Clinical examination
The vital signs were stable. A mass at the right frontal region could be palpated, about 5 cm in diameter, hard, fixed, with no obviously red, swollen, or tender of the superficial scalp.
Imaging studies
Cranial CT scan showed an mixed iso-/hyperdensity mass in the right frontal cranial bone, about 60 to 198 Hu, measuring 34 × 21 mm, with clear margin. The peripheral bone appeared destructive absorption. The MR was contraindicated for metal implant (Figure 1 ).
Surgery, pathologic result, and postoperative course
The patient underwent total tumor resection through right frontal approach on 24 December, 2013. The tumor eroded both the external and internal lamina of the cranial bone. The tumor was solid, soft, tender, pale white, rich blood supplied, and was adhesive to the underlying dura mater. The dura mater was yet intact, sparing the parenchyma of the cortex. The intraoperative rapid frost pathologic examination revealed malignant changes, and so after tumor resection, the adjacent dura mater was removed as well which was reconstructed with self aponeurosis. The peripheral bone was resected to the negative zone. The excision margin was about 2 cm.
The pathologic examination reported amelanotic melanoma of intermediate grade, with positive of HMB45, MelanA (sparsely), S-100, Vimentin, CD99, SMA (sparsely), and CD34, and negative of CK, EMA, CEA, CK5/6, CK8/ 18, TTF-1, SYN, CD56, CgA, Desmin, MyoD1, TFE3, PAS, and PR. The Ki-67 was 20% to 30% (±) (Figure 2) .
The further examination includes CT scan of the chest, abdominal, and the pelvic region and the PET scan of the whole brain and body, which were all negative.
The patient was discharged 3 days after the operation with no complications and went on for adjuvant radiotherapy and chemotherapy (concomitant stereotactic radiosurgery + ipilimumab). For more than 5 months of follow-up, the patient recovers well with no recurrence or related sequelae.
Review of cases and literature
We summarized the CNS melanocytic lesions of our neurosurgery department since 2008. Then we used the search engine of PubMed with keywords of melanoma or melanomatosis or melanocytoma or melanocytosis, and CNS and primary and further searched with keywords of CNS or brain or cranial or spinal, and amelanotic.
Thirty-two cases of CNS melanocytic lesions of our department were defined since 2008. Forty-three English reports of CNS melanocytic lesions and 14 reports about CNS amelanotic melanoma were searched. The details were summarized in the tables (Tables 1, 2, and 3).
Discussion
Primary melanocytic neoplasms of the CNS belong to the tumors of the meninges, further classified as diffuse melanocytosis, melanocytoma, malignant melanoma, and meningeal melanomatosis. The incidence is 0.06% to 0.1% of melanocytoma and 0.005/100,000 of melanoma. Other subtypes are rare. There is a slight female predisposition, with the ratio of F:M = 1.5:1. The age range of melanocytoma is 9 to 73 years, most frequently from 45 to 50 years, and of the primary nodular melanoma is 15 to 71 years, averaging 43 years. The symptoms and signs are secondary to either the local effects on the CNS parenchyma or the accompanying hydrocephalus. The rapid progress with increasing ICP resulting in irritability, vomiting, lethargy, seizures, and so on may suggest malignant transformation. The diagnosis of melanocytic lesions relies on the histopathological examination. Most benign and malignant melanocytic lesions display melanin pigment distributed within tumor cells, tumor stroma, and the cytoplasm of tumoral macrophages (melanophages). Tumor with CNS invasion or elevated mitotic activity is classified as intermediate grade melanocytic neoplasms. Malignant melanoma is more pleomorphic, has more anaplastic nuclei, higher cell density, and unequivocal invasion or coagulative necrosis. Rare melanocytomas and occasional primary melanomas will not demonstrate melanin pigment, complying with 'amelanotic' Amelanotic melanoma may arise from normal melanoma with amelanotic transformation or detergent of the tumor cell. Histopathological and immunohistochemistry examinations are highly sensitive to amelanotic melanoma. The neuroimaging performance depends on the content of melanin. Isiklar et al. [1] classified the MR performance into four groups: a) The melanotic group, with hyperintense on T1 and hypointense on T2. b) The amelanotic group, with iso-/hypointense on T1 and iso-/ hyperintense on T2. c) The mixed group, suiting neither the two criteria. d) The hemorrhagic group, with characteristics of intra-/peri-tumoral hemorrhage. Gaviani et al. [2] reported that the T1 signal has positive correlation with the content of melanin, while T2 signal has no such correlation but is more sensitive to tiny loci.
Early in 1980s, Willis et al. pointed out that the diagnosis of 'primary' has to meet three critical conditions: a) The skin or eyeballs are negative of melanoma. b) The skin or eyeballs have no history of melanoma resection. c) The internal organs are negative of metastasis of melanoma. Savitz [3] thought that the systemic melanocytic lesions are very likely to metastases to CNS while the primary loci are quite indolent. Winkelman et al. [4] reported that 44% of all melanocytic lesions have CNS metastasis at autopsy, so that the 'primary' can only be confirmed after autopsy. So every melanocytic neoplasm may be a systemic disease, and the 'primary CNS melanocytic lesion' is just a subtype with CNS as the single manifestation clinically.
There are approximately more than 60 papers describing primary CNS melanocytic lesions, with about 40 are in English, dated from 1972 to 2013. The number of cases ranged from one to ten. The symptoms are various according to the location of the tumor and so are the neuroimaging performance relating to the content of the melanin, as mentioned before. About 14 papers referred to CNS amelanotic melanoma, from 1981 to 2012. Most are case reports, including two primary intraspinal and two primary meningeal amelanotic melanoma, 22 intracerebral metastasis, one intraventricular metastasis, and three cases with no details. Schuknecht et al. [5] reported two primary meningeal amelanotic melanoma in 1990, serving as the only paper describing primary CNS amelanotic melanoma. There are totally 32 primary or metastatic CNS melanocytic lesions of our department since 2008. The cases diagnosed earlier are not included because of the controversial diagnosis criterion before the 2007 WHO classification which are widely adopted. The location involves all the CNS, from supratentorial to intraspinal region. Due to the unspecific resemblance, there were only few cases which were diagnosed before surgery, and the differentiations were quite variable. The most common differentiations are tumors of the meninges, which belong to the same group of the melanocytic lesions, such as meningioma and the mesenchymal tumors. The hematopoietic neoplasms, cavernous hemangioma, and even the cystic lesions are also involved especially when there are hemorrhage, cystic changes, or necrosis, and so on. One of them was suspected as amelanotic melanoma. Our case is the second one with definite diagnosis of amelanotic melanoma. The clinical characteristics of amelanotic melanoma are similar to other melanocytic lesions, with the neuroimaging performance as the major difference. Also, during the operation, the amelanotic melanoma appears more pale white, and the microscopic examination reviews the lacking of melanin. As the overall examinations were all negative, the primary intracranial amelanotic melanoma was confirmed.
The prognosis of amelanotic melanoma is not quite different from other CNS melanoma. Melanocytoma lacks anaplastic features, but a few undergo local recurrences. Intermediate grade melanocytic tumors typically invade the CNS. A rare example of malignant transformation of a melanocytoma has been reported. Malignant melanoma is highly aggressive and radioresistant, has poor prognosis, and prone to metastasize. The prognosis of diffuse melanosis is poor even in the absence of histologic malignancy. The prognosis of the primary CNS melanocytic lesions appears to be better than metastatic examples. For our case of primary intracranial amelanotic melanoma, total resection was achieved as well as excessive removal of invaded cranial bone and adjacent meninges. The experience of postoperative adjuvant therapy is quite poor. We adopted the radiotherapy and chemotherapy regimen of concomitant stereotactic radiosurgery + ipilimumab, referring to the NCCN guidelines for melanoma (2.2015 version) . With adjuvant radiotherapy and chemotherapy, the patient is tumor-free 5 months later and is still under follow-up.
Conclusions
CNS amelanotic melanoma is quite rare. The clinical characteristics are similar to other melanocytic lesions, with the neuroimaging performance as the major difference. The prognosis of amelanotic melanoma is not quite different from other CNS melanoma and appears to be better than the metastatic cases, particularly if localized and complete resection is possible.
